Two Sigma Investments LP Has $3.65 Million Holdings in Abbott Laboratories (ABT)

Two Sigma Investments LP raised its position in Abbott Laboratories (NYSE:ABT) by 27.9% during the fourth quarter, HoldingsChannel.com reports. The fund owned 63,956 shares of the healthcare product maker’s stock after purchasing an additional 13,966 shares during the quarter. Two Sigma Investments LP’s holdings in Abbott Laboratories were worth $3,650,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. Rowland & Co. Investment Counsel ADV bought a new stake in shares of Abbott Laboratories during the 4th quarter valued at about $102,000. Icon Wealth Partners LLC bought a new stake in shares of Abbott Laboratories during the 4th quarter valued at about $102,000. Tributary Capital Management LLC bought a new stake in shares of Abbott Laboratories during the 3rd quarter valued at about $106,000. Cerebellum GP LLC bought a new stake in shares of Abbott Laboratories during the 4th quarter valued at about $133,000. Finally, Aevitas Wealth Management Inc. bought a new stake in shares of Abbott Laboratories during the 4th quarter valued at about $160,000. Hedge funds and other institutional investors own 72.37% of the company’s stock.

Shares of Abbott Laboratories stock opened at $58.45 on Thursday. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.26 and a quick ratio of 1.86. The stock has a market capitalization of $103,278.19, a price-to-earnings ratio of 23.66, a PEG ratio of 1.75 and a beta of 1.50. Abbott Laboratories has a 52-week low of $42.31 and a 52-week high of $64.60.



Abbott Laboratories (NYSE:ABT) last issued its earnings results on Wednesday, January 24th. The healthcare product maker reported $0.74 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.01. The business had revenue of $7.59 billion during the quarter, compared to analysts’ expectations of $7.38 billion. Abbott Laboratories had a net margin of 1.74% and a return on equity of 13.88%. The business’s revenue for the quarter was up 42.3% compared to the same quarter last year. During the same period in the previous year, the company earned $0.65 earnings per share. research analysts predict that Abbott Laboratories will post 2.86 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, May 15th. Shareholders of record on Friday, April 13th will be issued a $0.28 dividend. The ex-dividend date of this dividend is Thursday, April 12th. This represents a $1.12 annualized dividend and a yield of 1.92%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 44.80%.

In other news, EVP Stephen R. Fussell sold 13,313 shares of the business’s stock in a transaction that occurred on Tuesday, January 30th. The shares were sold at an average price of $62.84, for a total transaction of $836,588.92. Following the completion of the transaction, the executive vice president now directly owns 152,343 shares of the company’s stock, valued at $9,573,234.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Jared Watkin sold 996 shares of the business’s stock in a transaction that occurred on Thursday, March 1st. The shares were sold at an average price of $58.87, for a total transaction of $58,634.52. Following the transaction, the senior vice president now directly owns 69,511 shares of the company’s stock, valued at $4,092,112.57. The disclosure for this sale can be found here. Insiders sold 124,261 shares of company stock valued at $7,559,987 over the last ninety days. Corporate insiders own 0.74% of the company’s stock.

A number of equities research analysts have recently weighed in on the stock. Leerink Swann reaffirmed a “market perform” rating and set a $68.00 target price (up previously from $60.00) on shares of Abbott Laboratories in a research note on Thursday, January 25th. Bank of America boosted their price objective on shares of Abbott Laboratories from $60.00 to $70.00 in a research note on Wednesday, January 24th. They noted that the move was a valuation call. BMO Capital Markets boosted their price objective on shares of Abbott Laboratories from $65.00 to $70.00 and gave the stock an “outperform” rating in a research note on Thursday, January 25th. Stifel Nicolaus boosted their price objective on shares of Abbott Laboratories from $63.00 to $71.00 and gave the stock a “buy” rating in a research note on Thursday, January 25th. Finally, Barclays boosted their price objective on shares of Abbott Laboratories from $66.00 to $70.00 and gave the stock an “overweight” rating in a research note on Thursday, January 25th. Seven analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $65.47.

TRADEMARK VIOLATION WARNING: This article was originally published by Dakota Financial News and is the property of of Dakota Financial News. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at https://dakotafinancialnews.com/2018/04/12/two-sigma-investments-lp-has-3-65-million-holdings-in-abbott-laboratories-abt.html.

About Abbott Laboratories

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; and anti-infective clarithromycin, as well as provides influenza vaccine and products that regulate physiological rhythm of the colon.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply